Cancer Medicine
Author Guidelines
Contents
1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details
1. SUBMISSION
Thank you for your interest in Cancer Medicine. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/cancermedicine
The submission system will prompt you to use an ORCID iD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.
Click here for more details on how to use ScholarOne
This journal does not process pre-submission enquiries. If you are unsure whether your paper is within the scope of the journal, please consult the Aims and Scope section of the guidelines below, and other published papers in Cancer Medicine.
Data protection:
By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognise the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
Preprint policy:
Wiley believes that journals publishing for communities with established pre-print servers should allow authors to submit manuscripts which have already been made available on a non-commercial preprint server. Allowing submission does not, of course, guarantee that an article will be sent out for review. It simply reflects our belief that journals should not rule out reviewing a paper simply because it has already been available on a non-commercial server. Please see below for the specific policy language.
However, Wiley also knows that the use of preprint servers is not universally accepted and that individual journals and/or societies may approach submission of preprints differently.
This journal will consider for review articles previously available as preprints on non-commercial servers such as ArXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, etc. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.
For help with submissions, please contact: cancermed@wiley.com
We look forward to your submission.
2. AIMS AND SCOPE
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery
Cancer Prevention
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach
Bioinformatics
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers
We aim to be a truly global forum for high-quality cancer research, and we think that the best research should be published and made widely accessible as quickly as possible. Cancer Medicine publishes papers submitted directly to the journal and those referred from a select group of prestigious journals published by Wiley-Blackwell. List available here. Cancer Medicine is a Wiley Open Access journal, one of a new series of peer reviewed titles publishing quality research with speed and efficiency. For further information visit the Wiley Open Access website.
Notice: Cancer Medicine is receiving a very high number of “biomarker” papers whereby one miRNA or lncRNA is suggested to be a marker for a cancer or another pathologic condition. Cancer Medicine focuses on mechanistic data and not on cataloguing miRNAs or lncRNAs or associating them empirically with pathology, without serious rationale and in certain instances using superficial data or results transferred from other systems, as recently pointed out by Pub-Peer. Cancer Medicine will not review these manuscripts unless the author sends a preliminary inquiry making a case why this is different from the previous models and truly relevant for molecular medicine. This inquiry will be assessed by the Editorial Board Members experts in the area.
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
Cancer Medicine publishes:
• Original Research Articles provide insight into the field and are the journal’s primary mode of scientific communication. They must report well-conducted research with conclusions supported by the data presented in the paper. They also include well-designed quantitative studies and meta-analyses.
• Reviews The journal encourages solicited and unsolicited Review Articles on subjects of topical interest.
• Methods Papers Report detailing new method or improvement to existing method, evaluating new developments in comparison with conventional techniques where possible, and demonstrating its practical applications.
• Editorials are by invitation only.
• Letters to the Editor entail focused concerns, critiques or questions that might require further clarification or provide an alternative perspective. The Letter should refer to an article in a previously published issue (within the last calendar year) of Cancer Medicine. Authors of the focal article will be invited to respond. Letters to Editor will be peer-reviewed.
• Registered Reports are designed to eliminate publication bias and incentivize best scientific practice. Registered Reports are a form of empirical article in which the methods and proposed analyses are pre-registered and reviewed prior to research being conducted. This format is designed to minimize bias, while also allowing complete flexibility to conduct exploratory (unregistered) analyses and report serendipitous findings. The cornerstone of the Registered Reports format is that authors submit as a Stage 1 manuscript an introduction, complete and transparent methods and the results of any pilot experiments (where applicable) that motivate the research proposal, written in the future tense. These proposals will include a description of the key research question and background literature, hypotheses, experimental design and procedures, analysis pipeline, a statistical power analysis and full description of planned comparisons. Submissions, which are reviewed by editors, peer reviewers, and our statistical editor, meeting the rigorous and transparent requirements for conducting the research proposed, are offered an in-principle acceptance, meaning that the journal guarantees publication if the authors conduct the experiment in accordance with their approved protocol. Following data collection, authors prepare and resubmit a Stage 2 manuscript that includes the introduction and methods from the original submission plus their obtained results and discussion. The manuscript will undergo full review; referees will consider whether the data test the authors’ proposed hypotheses by satisfying the approved outcome-neutral conditions, will ensure authors adhered precisely to the registered experimental procedures, and will review any unregistered post hoc analyses added by the authors to confirm they are justified, methodologically sound and informative. At this stage, authors must also share their data (see also Wiley’s Wiley’s Data Sharing and Citation Policy) and analysis scripts on a public and freely accessible archive such as Figshare or Dryad. Additional details, including template reviewer and author guidelines can be found by clicking the link to the Open Science Framework from the Center for Open Science (see also Chambers et al. 2014) or in our Registered Reports Author Guidelines.
There is no word limit for general and Registered Reports.
Papers of a primarily methodical nature are welcomed.
The Journal does not publish case reports; authors of case reports are encouraged to submit to Wiley’s open access journal Clinical Case Reports.
4. PREPARING YOUR SUBMISSION
Parts of the Manuscript
Manuscripts should be submitted as a Word, RTF, or PDF file for peer-review submission and must be written in English. It is not necessary to try to replicate the layout of the journal in your submission, we ask only that you supply your manuscript in a clear, generic and readable layout, and ensure that all relevant sections are included. Our production process will take care of all aspects of formatting and style.
Through May 31, 2021, Cancer Medicine employs a double-blind review process in which author and reviewer identities are confidential. Please note that as of June 1, 2021 Cancer Medicine will move to a single-blind peer review process. After June 1, authors will not need to blind their manuscripts prior to submission.
Please upload a title page for your manuscript that is separate from the rest of the main document. It should include:
1. Title
Authors’ names
iii. Authors’ affiliations
Authors’ contact details (especially e-mail address) for the person to whom the proof notification is to be sent.
Acknowledgements, including details of funding bodies with grant numbers
Ethical approval statement
vii. Clinical trial registration number (if applicable)
viii. Data availability statement
Please note, any citations of your previously published work must also be blinded prior to submission
2. Please upload the main manuscript without identifying author information. It should include:
i. Title page WITHOUT authors’ names or authors’ affiliations
ii. Abstract and 4–6 keywords
iii. Text
iv. Literature cited
v. Tables
vi. Figure legends
Note: Please provide at least three recommended reviewers for your paper. This will greatly help our editors locate and secure available peer-reviewers and will also accelerate the review of your paper.
Title
The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips).
Authorship
For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in the Editorial Policies and Ethical Considerations section. PLEASE NOTE: Changes to the author list cannot be made at revision stage. If you wish to add/remove authors, please contact the Editorial office at cancermed@wiley.com. The corresponding author should clearly mention in the cover letter where and how each newly added author made a contribution, and no authors will be added post acceptance.
Acknowledgments
Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.
Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.
Funding Statement
See ‘Funding’ section in Editorial Policies and Ethical Considerations for details on what to include in this section.
Data availability statement
See 'Data Sharing and Data Accessibility' section in Editorial Policies and Ethical Considerations for details on publishing your data availability statement to confirm the presence or absence of shared data.
Abstract
Please provide an abstract.
Keywords
Please provide 1-4 keywords. Keywords should be selected from the list that generates during submission. If you have any suggestions for new keywords, please contact the editorial office at cancermed@wiley.com
References
The completeness and content of your reference list is more important than the format chosen, it is not necessary to try to replicate the journal’s own style. However, a clear and consistent, generic style will assist the accuracy of our production processes. A guide to the minimum elements required for successful reference linking appears below. The final journal output will use the ‘Vancouver’ style of reference citation. If your manuscript has already been prepared using the ‘Harvard’ system, we are quite happy to receive it in this form.
Minimum reference information:
Journal Article
Author(s) in full
Year of publication
Article title
Journal title (preferably not abbreviated)
Volume number
Issue number
Page range
Book
Author(s) in full
Year of publication
Book title
Place of publication
Publisher
No. Pages
Book Chapter
Author(s) in full
Year of publication
Chapter title
Book Author/Editor
Book title
Place of publication
Publisher
Page range
Online resources
References to online research articles should always include a DOI, where available. When referring to other Web pages, it is useful to include a date on which the resource was accessed.
Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Preparing Figures
Although we encourage authors to send us the highest-quality figures possible, for peer-review purposes we are happy to accept a wide variety of formats, sizes, and resolutions.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Colour figures
Figures submitted in colour may be reproduced in colour online free of charge.
Cancer Medicine encourages you to designate one of the figures in your paper to be considered for the online journal cover and for potential publication on the official Wiley Open Access blog .
Guidelines for Cover Submissions
If you would like to send suggestions for artwork related to your manuscript to be considered to appear on the cover of the journal, please follow these general guidelines.
Appendices
Appendices will be published after the references and referred to in the text.
Supporting Information
Supporting information is information that is not essential to the article but that provides greater depth and background. It is hosted online, and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information. Note, if data, scripts or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.
General Style Points
The following links provide general advice on formatting and style.
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at http://www.bipm.fr for more information about SI units.
• Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
• Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.
Wiley Author Resources
Manuscript Preparation Tips
Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.
Editing, Translation and Formatting Support
Wiley Editing Services can greatly improve the chances of your manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting and figure preparation, Wiley Editing Services ensures that your manuscript is ready for submission.
By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
Editorial Review and Acceptance
Cancer Medicine accepts papers that are relevant to our readership and reflect valid science ie. conclusions drawn need to be substantiated by the data, but novelty, insight and impact are not paramount. Except where otherwise stated, manuscripts are double-blind peer reviewed. Papers will only be sent to review if the Editors-in-Chief determine that the paper meets the appropriate quality and relevance requirements. Wiley's policy on confidentiality of the review process is available here.
Appeal Requests
Manuscripts that have been rejected from the journal directly or after peer review are not usually reconsidered. Authors should only appeal when a factual error in a reviewer report or if the authors believe a misunderstanding seems to be the main reason for the rejection. Authors who wish to request reconsideration of a rejected manuscript should contact the Editorial Office (cancermed@wiley.com). Requests must include the manuscript ID and a detailed description of why the authors believe the paper should be reconsidered. Appeal requests will be evaluated by the Editor-in-Chief and/or Deputy Editor to determine if an appeal will be permitted. The author will be contacted with the decision, and if the request is approved, the manuscript will be reassigned to another Associate Editor for consideration. Editorial decisions that are the outcome of an appeal procedure are final and cannot be appealed again.
Data Sharing and Data Accessibility
Cancer Medicine recognizes the many benefits of archiving research data. Cancer Medicine expects you to archive all the data from which your published results are derived in a public repository. The repository that you choose should offer you guaranteed preservation (see the registry of research data repositories at https://www.re3data.org/) and should help you make it findable, accessible, interoperable, and re-useable, according to FAIR Data Principles https://www.force11.org/group/fairgroup/fairprinciples. All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the policy. If you cannot share the data described in your manuscript, for example for legal or ethical reasons, or do not intend to share the data then you must provide the appropriate data availability statement. Cancer Medicine notes that FAIR data sharing allows for access to shared data under restrictions (e.g., to protect confidential or proprietary information) but notes that the FAIR principles encourage you to share data in ways that are as open as possible (but that can be as closed as necessary). Sample statements are available here. If published, all statements will be placed in the heading of your manuscript.
Data Citation
Please also cite the data you have shared, like you would cite other sources that your article refers to, in your references section. You should follow the format for your data citations laid out in the Joint Declaration of Data Citation Principles, https://www.force11.org/datacitationprinciples:
[dataset] Authors; Year; Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI)
Data collection and presentation
Presented data must represent the findings in an unbiased, accurate and transparent manner. This includes appropriate statistical analysis and image processing. The Editors reserve the right to request minimally processed versions of figures and the source data that were used to assemble the figure from the authors of a paper under consideration, or of a paper already published in the journal.
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/20457634/homepage/forauthors.html
